Rigel Pharmaceuticals, Inc. (RIGL) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 15 analysts17.0% Above Target
RIGL trades 17.0% above Wall Street's consensus target of $27.33.
Current Price$32.91
Average Target$27.33
Target
Current
Low$2.00
Median$38.00
High$42.00
Analyst Target Range
Forward P/E10.5x
(Value)
PEG Ratio—
Implied Growth-83.0%
(Declining)
Analyst Spread146.4%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes RIGL achieves its forward estimates and maintains a stable P/E multiple of 10.5x. This scenario reflects the blended consensus of 15 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
RIGL Price Target Analysis
Updated June 21, 2026As of June 21, 2026, Rigel Pharmaceuticals, Inc. (RIGL) has a Wall Street consensus price target of $27.33, based on estimates from 15 covering analysts. With the stock currently trading at $32.91, this represents a potential downside of -17.0%. The company has a market capitalization of $609M.
Analyst price targets range from a low of $2.00 to a high of $42.00, representing a 146% spread in expectations. The median target of $38.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, RIGL trades at a trailing P/E of 1.7x and forward P/E of 10.5x. Analysts expect EPS to grow -83.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $35.62, with bear and bull scenarios of $22.44 and $46.94 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+85.1%
Industry Consensus
Avg Forward P/E
86.1x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRTAProthena Corporation plc | $468M | $8.93 | $19.00 | +112.8% | Buy | 191.2x | 28 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 RAREUltragenyx Pharmaceutical Inc. | $2.7B | $27.44 | $48.36 | +76.2% | Buy | — | 33 |
 HALOHalozyme Therapeutics, Inc. | $8.1B | $68.55 | $88.25 | +28.7% | Buy | 8.5x | 27 |
 PTCTPTC Therapeutics, Inc. | $6.6B | $78.98 | $95.83 | +21.3% | Buy | 89.1x | 26 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.62 | $33.67 | +55.7% | Buy | 55.6x | 37 |
 IMVTImmunovant, Inc. | $7.3B | $35.34 | $45.00 | +27.3% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.3B | $26.21 | $34.00 | +29.7% | Buy | 131.6x | 12 |
 CABACabaletta Bio, Inc. | $463M | $2.84 | $16.33 | +475.0% | Buy | — | 12 |
 KYMRKymera Therapeutics, Inc. | $7.4B | $90.43 | $112.60 | +24.5% | Buy | — | 26 |
RIGL — Frequently Asked Questions
Quick answers to the most common questions about buying RIGL stock.
What is the RIGL stock price target for 2026?
RIGL's consensus price target is $27.33, -17.0% below the current price of $32.91. The 15 analysts tracking RIGL see downside risk at present valuations.
Is RIGL a buy, sell, or hold?
RIGL has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $27.33 implies -17.0% downside from current levels.
Is RIGL stock overvalued or undervalued?
With a forward P/E of 10.4526x, RIGL trades at a relatively low valuation. The consensus target of $27.33 implies -17.0% move, suggesting the market may be pricing in risks.
How high can RIGL stock go?
The most bullish Wall Street analyst has a price target of $42 for RIGL, while the most conservative target is $2. The consensus of $27.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $47 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover RIGL stock?
RIGL is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 7 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the RIGL stock forecast?
The 12-month RIGL stock forecast based on 15 Wall Street analysts shows a consensus price target of $27.33, with estimates ranging from $2 (bear case) to $42 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $36, with bear/bull scenarios of $22/$47.
What is RIGL's fair value based on fundamentals?
Our quantitative valuation model calculates RIGL's fair value at $36 (base case), with a bear case of $22 and bull case of $47. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
What is RIGL's forward P/E ratio?
RIGL trades at a forward P/E ratio of 10.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 1.7x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy RIGL stock?
Analysts are cautious on RIGL, with 0 Sell ratings and a price target of $27.33 (-17.0% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do RIGL price targets vary so much?
RIGL analyst price targets range from $2 to $42, a 146% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $27.33 consensus represents the middle ground. Our model's $22-$47 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare